A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Janssen Research & Development, LLC
AVEO Pharmaceuticals, Inc.
PDS Biotechnology Corp.
Merus B.V.
Merck Sharp & Dohme LLC
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
R-Pharm
Merck Sharp & Dohme LLC
Incyte Corporation
Rakuten Medical, Inc.
EMD Serono
GlaxoSmithKline
Rakuten Medical, Inc.
Akeso
GlaxoSmithKline
Shanghai Miracogen Inc.
Soligenix
Bristol-Myers Squibb
CEL-SCI Corporation
Merck KGaA, Darmstadt, Germany
AstraZeneca
Pfizer
Bristol-Myers Squibb
Sinocelltech Ltd.
Incyte Corporation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pierre Fabre Medicament
Sanofi
Merck KGaA, Darmstadt, Germany
Oncolytics Biotech
Merck KGaA, Darmstadt, Germany
Navidea Biopharmaceuticals
INSYS Therapeutics Inc
Daiichi Sankyo
AstraZeneca
Vical
Introgen Therapeutics
Introgen Therapeutics